Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma.

Details

Ressource 1Download: 21975223.pdf (12268.80 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_4E3F6092C42F
Type
Article: article from journal or magazin.
Collection
Publications
Title
Identification of stromal proteins overexpressed in nodular sclerosis Hodgkin lymphoma.
Journal
Proteome Science
Author(s)
Kischel P., Waltregny D., Greffe Y., Mazzucchelli G., De Pauw E., de Leval L., Castronovo V.
ISSN
1477-5956 (Electronic)
ISSN-L
1477-5956
Publication state
Published
Issued date
2011
Peer-reviewed
Oui
Volume
9
Number
1
Pages
63
Language
english
Abstract
ABSTRACT: Hodgkin lymphoma (HL) represents a category of lymphoid neoplasms with unique features, notably the usual scarcity of tumour cells in involved tissues. The most common subtype of classical HL, nodular sclerosis HL, characteristically comprises abundant fibrous tissue stroma. Little information is available about the protein composition of the stromal environment from HL. Moreover, the identification of valid protein targets, specifically and abundantly expressed in HL, would be of utmost importance for targeted therapies and imaging, yet the biomarkers must necessarily be accessible from the bloodstream. To characterize HL stroma and to identify potentially accessible proteins, we used a chemical proteomic approach, consisting in the labelling of accessible proteins and their subsequent purification and identification by mass spectrometry. We performed an analysis of potentially accessible proteins in lymph node biopsies from HL and reactive lymphoid tissues, and in total, more than 1400 proteins were identified in 7 samples. We have identified several extracellular matrix proteins overexpressed in HL, such as versican, fibulin-1, periostin, and other proteins such as S100-A8. These proteins were validated by immunohistochemistry on a larger series of biopsy samples, and bear the potential to become targets for antibody-based anti-cancer therapies.
Pubmed
Open Access
Yes
Create date
29/02/2012 10:16
Last modification date
20/08/2019 14:03
Usage data